Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in retinal amacrine cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 11934
Sealed predictions
- CELF4 in dopamine neurons, braak-0.16 (p 0.680) → -0.55 (p 0.125)receipt 11941
Swarm cases
receipt 11941: CELF4 in dopamine neurons, braak
- power
- full sample -0.38 (p 0.118, n 18), 95% CI -0.72 to +0.10. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.32 (p 0.198, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.50 (p 0.033, n 18). not the mix.
- skeptic
- leave-one-out range -0.51 to -0.30, sign flips 0; without severely affected donors -0.38 (p 0.118, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CELF4 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts